Application of High-Dose Intermittent Addition of GnRH-a Luteal Support in Infertility Patients Undergoing Fresh Embryo Transfer Induced by Antagonist Therapy for Ovulation Induction

WU Qingying; LI Aixiang; ZHOU Lingyun

doi:10.3969/j.issn.1004-437X.2026.13.015

Abstract：Objective To observe the application effect of high-dose intermittent addition of gonadotropin-releasing hormone agonist(GnRH-a)in the treatment of infertility patients undergoing fresh embryo transfer induced by antagonist therapy for ovulation induction.Methods A retrospective analysis was conducted on the data of 85 infertile patients who underwent in vitro fertilization-embryo transfer(IVF-ET)treatment at the Reproductive Medicine Center,Henan Province Reproductive Maternity Hospital from June 2022 to June 2023.Among them,42 patients were included in the control group with an antagonist regimen and luteal support(intramuscular injection of progesterone+0.1 mg GnRH-a on the 6th day after egg retrieval)+IVF-ET,while 43 patients were included in the observation group with an antagonist regimen+luteal support(intramuscular injection of progesterone+0.05 mg,0.1 mg GnRH-a on the 6th,8th,and 10th day after egg retrieval)+IVF-ET.The treatment related data of two groups of patients were saved completely,and patient information was carefully reviewed.The main outcome indicators of the two groups were recorded,including hormone levels at 14 days of embryo transfer[serum human chorionic gonadotropin(hCG),estradiol(E2),progesterone],ovulation quality(number of 2PN fertilized,number of high-quality embryos,number of retrieved eggs,and endometrial thickness on the trigger day),clinical outcomes,and the occurrence of adverse reactions in patients during luteal support medication.Results The serum hCG,E2,and progesterone levels in the observation group were higher than those in the control group at 14 days of embryo transfer(P＜0.05).There was no significant difference in the number of 2PN fertilizations,high-quality embryos,number of retrieved eggs,endometrial thickness on trigger day,early miscarriage rate,and ectopic pregnancy rate between the two groups(P＞0.05).The clinical pregnancy rate and live birth rate in the observation group were higher than those in the control group(P＜0.05).There was no difference in the incidence of adverse reactions during the luteal phase support medication between the two groups(P＞0.05).Conclusion The application of high-dose intermittent addition of GnRH-a luteal support in the treatment of infertility patients undergoing fresh embryo transfer induced by an antagonist regimen can achieve good clinical outcomes,have a good impact on patient related hormone levels,improve clinical pregnancy rate and live birth rate,and may become a more suitable luteal support regimen for promoting ovulation and inhibiting fresh embryos with an antagonist regimen.